A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.
Clinical trial NCT05231850 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05231850
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-01
- Primary completion
- 2023-09-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.